To develop our business we are in the process of opening new offices in Europe and Germany. By end of this quarter the process will be over, said Ajay Simha, director, SysArris Software Pvt Ltd. Talking to Biopectrum Simha said we started our Indian operation in 1993. Since then our main focus was on exports. But only in the last couple of years we are looking at the Indian Market. The software developed by our team of 35 with functional knowledge in both biology and software skills is used in pharmaceutical /biotech companies around the world, he added. Companies like Amgen, AstraZeneca, Boots Healthcare International, Pfizer International, Parke-Davis - are some of the customers of SysArris.

Operating from USA, SysArris has channel partners in Australia and Hong Kong to meet the requirements of the customers of Asia-Pacific region, Simha said. "We have been following the need-based approach and utmost care is taken towards the customers' satisfaction. SysArris would leverage on its core strength both in functional and software areas. Besides the functional knowledge on life sciences the team has knowledge of the drug validation process. And decades of experience with the pharmaceutical industry and biotechnology expertise ensures us to provide a complete bench -to bottle software solutions for our clients," he noted.

"We have adopted an integrated team work effort and offer solutions in data mining and visualization and for gene discovery programs, functional genomics, recombinant DNA technologies, targeted research or pharmacogenomics using advanced programming methodologies and accurate algorithms resulting in accelerated throughput and maximized solutions. From developing software to analyze and manage complex biological information and accelerate the drug discovery process, we assist pharmaceutical companies in all phases of the drug development cycle. And also provide solutions for optimizing images that are captured during various experiments like HTS, Microarray and other related spotting experiments for biotech needs," he added.